Home
Astrazeneca Pharma India Ltd Board of Directors
Board of Directors at Astrazeneca Pharma India Ltd
Executive Director
Non Executive Director
Chairman & Independent Directo
Non-Exec. & Independent Dir.
Managing Director
Key Highlights
- Narayan K Seshadri continues to serve as the Chairman & Independent Directo in 2024, maintaining the same position as in the previous year.
- Revathy Ashok continues to serve as the Non-Exec. & Independent Dir. in 2024, maintaining the same position as in the previous year.
- Shilpa Divekar Nirula joins the board as Non-Exec. & Independent Dir., in a new position in 2024. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Sanjeev Panchal joins the board as Managing Director, in a new position in 2024. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Hooi Bien Chuah joins the board as Non Executive Director, in a new position in 2024. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.

Astrazeneca Pharma India Ltd
NSE: ASTRAZEN
Share Price
Last Ten Days Market Price
Date | |
---|---|
12 May 2025 | 8118.6 |
09 May 2025 | 7992.35 |
08 May 2025 | 8176.2 |
07 May 2025 | 8186.4 |
06 May 2025 | 8201.3 |
05 May 2025 | 8350.25 |
02 May 2025 | 8369.85 |
30 Apr 2025 | 8665.5 |
29 Apr 2025 | 8795.9 |
28 Apr 2025 | 8839.6 |
Company Fundamentals for Astrazeneca Pharma India Ltd
Market Cap
20,296 Cr
EPS
67.1
P/E Ratio (TTM)
121.1
P/B Ratio (TTM)
29.9
Day’s High
8253.6
Day’s Low
7808.95
DTE
0.0
ROE
18.9
52 Week High
9199.0
52 Week Low
5180.6
ROCE
23.9
Market Price of Astrazeneca Pharma India Ltd
1M
1Y
3Y
5Y
Astrazeneca Pharma India Ltd News Hub
AstraZeneca slumps on recording dismal Q1 performance
Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30
Read more
08 Aug 24
Astrazeneca Pharma India reports standalone net loss of Rs 11.79 crore in the June 2024 quarter
Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as ag
Read more
08 Aug 24
Astrazenenca Pharma gets CDSCO nod to import Durvalumab solutions
Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI
Read more
24 Sept 24
Astrazeneca Pharma India Ltd leads gainers in 'A' group
Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Firstsource Solutions Ltd and National Alumini
Read more
24 Sept 24